Head-to-head · Value Score
CoreAge Rx vs VevaRX
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, VevaRX a 68. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$99/mo
Save ~89% vs brand-nameVevaRX
#277 · Grade C · Watch List
Est. first month
$189/mo month-to-month (or $399 on a three-month prepay; its own page also prints $167 a month and a $467 total)
Save ~86% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 68 — an est. $99/mo first month, with no teaser step-up baked in. VevaRX isn't out of it: Readers in one of the thirty-six states listed who will confirm every figure in the cart, since the cards, the plan text and the cart disagree on almost every product.
CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | VevaRX |
|---|---|---|
| Value Score | 93 (A+) | 68 (C) |
| Est. first month | $99/mo | $189/mo month-to-month (or $399 on a three-month prepay; its own page also prints $167 a month and a $467 total) |
| Save vs brand-name | ~89% | ~86% |
| Semaglutide | $99/mo | $189/mo month-to-month (or $399 on a three-month prepay; its own page also prints $167 a month and a $467 total) |
| Tirzepatide | $149/mo | $467 per three-month prepay, auto-renewing with a three-month minimum (no monthly rate is published for tirzepatide) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | 36 states, listed |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
VevaRX
A thirty-six-state program selling semaglutide at $189 a month on a page that also prints $167, $399 and $467 for the same drug — and tirzepatide only as a three-month prepay whose advertised per-month equivalent does not divide.
Why it's a deal
- The states are published as a named list of thirty-six rather than an all-fifty claim, and the list is the one the site treats as operative
- A month-to-month option exists for semaglutide at $189, which is more than the tirzepatide side of the same business offers
- The three-month prepay totals are stated as totals — $399 and $467 — rather than only as per-month arithmetic, so the commitment can be priced
- Auto-renewal is disclosed plainly on the product pages: the plan renews every three months and can be canceled at any time
- A legal entity is published, and side products carry published prices rather than a consultation
The fine print
- The semaglutide page carries four prices for one drug, and two of them belong to tirzepatide: $189 a month and $399 for three months on the cards, then $167 a month or $467 for three months in the paragraph below them
- Tirzepatide is sold only as a three-month prepay at $467 with a three-month minimum, and the per-month equivalent advertised beside it does not divide: $467 over three months is $155.67, not the $149 printed
- Every side product publishes three different figures — one on the card, one in the plan text and one in the cart — and in at least one case the card is the wrong one
- A third price ladder sits in the terms and matches nothing sold anywhere on the site
- Another brand's domain appears in the terms as the site conducting the transactions, and the contact page's questions carry a different product's copy giving dosing instructions for a powdered drink
- Two opposite return policies are published: one page says compounded medication that has shipped cannot be returned, another promises results or your money back, and the terms say something different again
- No pharmacy is named, no clinician is named, no medical group is named and no 503A or 503B designation appears anywhere across sixteen pages
- No street address is published at all, and the only phone number appears in the terms as a text-message keyword rather than a support line
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to VevaRX.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.